Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Mar 9 · inside the Ichimoku cloud · RSI 97 (overbought) · MACD below its signal
None of the 29 investors followed here reported a position in SYGGF in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SYGGF trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 16, 2025 | Polygon Global Partners Llp | — | 900.00M | — |
| Dec 30, 2023 | Shaw (Simon James Blouet) | — | 0 | — |
| Dec 30, 2023 | Ward (John Christopher) | — | 0 | — |
| Dec 30, 2023 | Marsden (Richard James) | — | 0 | — |
| Dec 30, 2023 | Monk (Phillip David) | — | 0 | — |
| Dec 30, 2023 | Holgate (Stephen) | — | 0 | — |
| Dec 30, 2023 | Campbell (David Bruce) | — | 0 | — |
| Jun 10, 2023 | Polygon Global Partners Llp | — | 0 | — |
| Apr 25, 2023 | Polygon Global Partners Llp | — | 0 | — |
| Dec 30, 2022 | Campbell (David Bruce) | — | 0 | — |
| Dec 30, 2022 | Marsden (Richard James) | — | 0 | — |
| Dec 30, 2022 | Monk (Phillip David) | — | 0 | — |
| Dec 30, 2022 | Shaw (Simon James Blouet) | — | 0 | — |
| Dec 30, 2022 | Ward (John Christopher) | — | 0 | — |
| Dec 30, 2022 | Holgate (Stephen) | — | 0 | — |
| Oct 4, 2022 | Polygon Global Partners Llp | — | 4.29M | — |
| Jul 14, 2022 | Polygon Global Partners Llp | — | 0 | — |
| Jun 13, 2022 | Polygon Global Partners Llp | — | 2.04M | — |
| Apr 4, 2022 | Polygon Global Partners Llp | — | 1.47M | — |
| Mar 6, 2022 | Polygon Global Partners Llp | — | 2.00M | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 900.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +900.0% | ||
| 2025 | 14.0 | -1.8 | -64.6 | -24.8 | -98.8 | 200.0 | -66.7 | 0.0 | 100.0 | 0.0 | -50.0 | -90.0 | −100.0% |
| 2024 | -10.0 | 0.0 | 33.3 | -7.0 | 48.7 | -33.7 | -2.7 | -6.4 | -16.7 | 8.5 | 50.3 | -58.1 | −43.0% |
| 2023 | 15.6 | 13.0 | -32.6 | 52.8 | -52.1 | 14.3 | 9.3 | -24.5 | 19.8 | 33.9 | 0.0 | -58.7 | −59.7% |
| 2022 | -5.6 | -85.5 | -21.5 | -3.3 | 4.4 | 37.0 | -22.9 | -21.9 | 20.0 | -22.0 | 11.8 | -52.6 | −95.5% |
| 2021 | 17.5 | -3.8 | -2.7 | -24.5 | 39.2 | -0.5 | -10.9 | 0.7 | -8.0 | 43.2 | -1.8 | 4.3 | +39.3% |
| 2020 | 3.9 | -29.8 | 15.0 | -42.3 | 62.6 | −21.2% |
No analyst coverage for this instrument.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an investigative formulation of inhaled interferon beta (IFN-ß') for the treatment and prevention of severe viral lung infections in high-risk patient groups. The company was incorporated in 2003 and is headquartered in Southampton, the United Kingdom.
No recent headlines.